Selecta Biosciences, Inc. (NASDAQ:SELB) reached 57.45% versus a 1-year low price of $1.41. The stock was last seen 4.72% higher, reaching at $2.22 on 3/14/2019. At a recent session, the prices were hovering between $2.04 and $2.22. This company shares are 440.54% off its target price of $12 and the current market capitalization stands at $44.02M. The recent change has given its price a 8.06% lead over SMA 50 and -86.58% deficit over its 52-week high. The stock witnessed 15.03% gains, -59.34% declines and -84.14% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SELB’s volatility during a week at 14.31% and during a month it has been found around 10.39%.

Selecta Biosciences, Inc. (SELB) Top Holders

Institutional investors currently hold around $22 million or 53.3% in SELB stock. Look at its top three institutional owners: Polaris Venture Management Co. V, L.L.C. owns $3.41 million in Selecta Biosciences, Inc., which represents roughly 7.74% of the company’s market cap and approximately 15.48% of the institutional ownership. Similar statistics are true for the second largest owner, Orbimed Advisors Llc, which owns 1,579,064 shares of the stock are valued at $3.35 million. The third largest holder is Blackrock Inc., which currently holds $1.91 million worth of this stock and that ownership represents nearly 4.33% of its market capitalization.

Selecta Biosciences, Inc. 13F Filings

At the end of December reporting period, 31 institutional holders increased their position in Selecta Biosciences, Inc. (NASDAQ:SELB) by some 1,136,964 shares, 34 decreased positions by 2,165,783 and 6 held positions by 7,196,987. That puts total institutional holdings at 10,499,734 shares, according to SEC filings. The stock grabbed 5 new institutional investments totaling 230,786 shares while 17 institutional investors sold out their entire positions totaling 609,755 shares.

Selecta Biosciences, Inc. (SELB) Analyst Guide

Several analysts have released their opinion on Selecta Biosciences, Inc. (NASDAQ:SELB), with 3 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.4 average brokerage recommendation [T1].